We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
According to the INST team, till-date there is no study reported where a combination of two anti-leishmanial drugs has been delivered through nanomodification as a potential therapeutic strategy against visceral leishmaniasis.